Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aortic rupture24.03.04.009; 12.01.11.0070.000313%Not Available
Adverse event08.06.01.010--Not Available
Bacterial infection11.02.01.005--Not Available
Colon neoplasm16.13.02.001; 07.21.10.0010.000313%Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.001159%Not Available
Gastrointestinal motility disorder07.02.03.001--Not Available
Gastrointestinal neoplasm16.13.11.001; 07.21.04.002--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.001880%Not Available
Lymphoproliferative disorder16.21.02.001; 01.13.02.0010.000313%Not Available
Joint lock15.01.08.0040.000313%Not Available
Malnutrition14.03.02.0040.001880%Not Available
Mediastinal disorder22.09.03.001--Not Available
Metastatic neoplasm16.16.01.0070.000313%Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Cardiac valve disease02.07.02.001--Not Available
Anal cancer16.13.05.001; 07.21.05.0010.000470%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Gastrointestinal ulcer07.04.04.0020.000470%Not Available
Ill-defined disorder08.01.03.049--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.0040.000313%Not Available
Immunodeficiency10.03.02.0020.001253%Not Available
Adverse drug reaction08.06.01.009--Not Available
Bone marrow disorder01.05.01.0060.000783%Not Available
Cervix carcinoma stage 016.12.01.002; 21.06.02.002--Not Available
Demyelinating polyneuropathy17.09.04.003; 10.04.10.0070.000313%Not Available
Disease recurrence08.01.03.0500.002475%Not Available
Drug intolerance08.06.01.0130.005702%Not Available
Obstruction08.01.03.023--Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene